Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $2000.0.

  • vTv Therapeutics' Depreciation and Depletion fell 9090.91% to $2000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $47000.0, marking a year-over-year decrease of 5300.0%. This contributed to the annual value of $100000.0 for FY2024, which is 0.0% changed from last year.
  • Per vTv Therapeutics' latest filing, its Depreciation and Depletion stood at $2000.0 for Q3 2025, which was down 9090.91% from $3000.0 recorded in Q2 2025.
  • vTv Therapeutics' 5-year Depreciation and Depletion high stood at $33000.0 for Q4 2021, and its period low was $2000.0 during Q3 2025.
  • Moreover, its 5-year median value for Depreciation and Depletion was $22000.0 (2021), whereas its average is $21789.5.
  • As far as peak fluctuations go, vTv Therapeutics' Depreciation and Depletion soared by 1785.71% in 2021, and later tumbled by 9090.91% in 2025.
  • vTv Therapeutics' Depreciation and Depletion (Quarter) stood at $33000.0 in 2021, then fell by 6.06% to $31000.0 in 2022, then rose by 6.45% to $33000.0 in 2023, then changed by 0.0% to $33000.0 in 2024, then plummeted by 93.94% to $2000.0 in 2025.
  • Its Depreciation and Depletion stands at $2000.0 for Q3 2025, versus $3000.0 for Q2 2025 and $9000.0 for Q1 2025.